Across eight studies enrolling 13,243 patients, GLP-1 receptor agonists (GLP-1 RAs) produced striking reductions in core idiopathic intracranial hypertension (IIH) endpoints: papilledema risk fell 57% at 3 months (RR 0.430) and held at 53% reduction through 24 months. Headache frequency dropped 31% at 3 months; visual disturbances were roughly halved. Refractory IIH risk declined 30% at 3 months and remained 19% lower at two years compared to controls.
IIH — elevated cerebrospinal fluid pressure without identifiable cause — disproportionately affects women of reproductive age with obesity, and its current pharmacological mainstay, acetazolamide, is poorly tolerated long-term. The biological plausibility for GLP-1 RAs here is legitimate: these agents reduce choroid plexus fluid secretion, modulate intracranial venous pressure via weight loss, and may directly suppress CSF production through GLP-1 receptors expressed on choroid plexus epithelium — a mechanism entirely distinct from carbonic anhydrase inhibition.
That said, this meta-analysis warrants measured enthusiasm. The evidence base is almost entirely observational, heterogeneity is substantial on several endpoints (I² up to 79%), and confounding by indication is a serious concern — clinicians may preferentially prescribe GLP-1 RAs to higher-BMI patients already more likely to respond to weight reduction. The authors appropriately classify certainty as low. For a condition that can cause permanent vision loss, these signals are compelling enough to prioritize dedicated randomized controlled trials, but clinicians should not yet reposition GLP-1 RAs as standard IIH therapy.